Osteochondrosis: Pathogenetic Bioregulatory Limitations of Using the Drug Discus Compositum

Abstract

Treatment of osteochondrosis is one of the actual problems in the therapy of degenerative-dystrophic diseases of the musculoskeletal system [1]. The clinical studies have shown that osteochondrosis — a disease of the whole body, and therefore, interdisciplinary problem, relevant both for neurologists, as well as for orthopedists and general practitioners [2]. A brief review of clinical studies is presented demonstrating the relevance of using bioregulatory approach, Discus compositum and other combined bioregulatory drugs (CBD) [3–6]. The feature of CBD — the content of ultra-low doses (low dose, very-low dose antigen) of active substances that contribute to the recovery of the processes of self-regulation and detoxification in the body, activation of metabolism and regeneration/reparation processes. Bioregulatory action of CBD complements the effect of other medicines, combining well with them. Since the ultra-small doses are not metabolized in the body, CBD have no pharmacokinetics: they do not require additional energy and do not have a pharmacological stress on the body [3–6]. In this regard, they are well-tolerated by patients during chronic administration. Also, their application is helpful, if there are contraindications, side effects and the risk of complications when using other groups of drugs.

Keywords

• osteochondrosis
• bioregulatory approach
• combined bioregulatory drugs
• serum C-reactive protein
• Discus compositum
• Traumeel S
• Zeel T.